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Objective Syntometrine is an effective uterotonic agent used in
preventing primary postpartum haemorrhage but has adverse
effects including nausea, vomiting, hypertension and coronary
artery spasm. Carbetocin is a newly developed long-acting oxytocin
analogue that might be used as an uterotonic agent. We compare
the efﬁcacy and safety of intramuscular (IM) carbetocin with IM
syntometrine in preventing primary postpartum haemorrhage.
Design Prospective, double-blinded, randomised controlled trial.
Setting Delivery suite of a university-based obstetrics unit.
Population Women with singleton pregnancy achieving vaginal
delivery after and throughout 34 weeks.
Methods Three hundred and twenty-nine eligible women were
randomised to receive either a single dose of 100 microgram IM
carbetocin or 1 ml IM syntometrine (a mixture of 5 iu oxytocin
and 0.5 mg ergometrine) at the end of second stage of labour.
Main outcome measures Difference in haemoglobin drop
measured 2 days after delivery between the two groups.
Results There was no difference in the drop of haemoglobin
concentration within the ﬁrst 48 hours between the two groups.
The incidence of additional oxytocic injections, postpartum
haemorrhage (blood loss ‡ 500 ml) and retained placenta were also
similar. The use of carbetocin was associated with signiﬁcant lower
incidence of nausea (relative risk [RR] 0.18, 95% conﬁdence
interval [CI] 0.04–0.78), vomiting (RR 0.1, 95% CI 0.01–0.74),
hypertension 30 minutes (0 versus 8 cases, P < 0.01) and 60
minutes (0 versus 6 cases, P < 0.05) after delivery but a higher
incidence of maternal tachycardia (RR 1.68, 95% CI 1.03–3.57).
Conclusions IM carbetocin is as effective as IM syntometrine in
preventing primary postpartum haemorrhage after vaginal delivery.
It is less likely to induce hypertension and has a low incidence of
adverse effect. It should be considered as a good alternative to
conventional uterotonic agents used in managing the third
stage of labour.
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Introduction
Primary postpartum haemorrhage resulting from uterine
atony is a major cause of maternal morbidity and mortality.1,2
Various prophylactic strategies have been used to prevent this
potential life-threatening emergency. Systematic reviews have
concluded that active management of third stage of labour,
particularly the prophylactic use of uterotonic agents can sig-
niﬁcantly decrease the incidence of postpartum haemorrhage
compared with that of expectant management.3–6 An ideal
uterotonic agent should promote prompt, strong and sus-
tained uterine contractions after intramuscular (IM) injection
without any signiﬁcant adverse effects.
Syntometrine is a mixture of oxytocin and ergotamine, and
1 ml of syntometrine contains 5 iu oxytocin and 0.5 mg
ergometrine. This mixture combines the rapid onset of
action of oxytocin and the sustained effect of ergometrine
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third stage of labour. IM syntometrine is shown to be as effec-
tive as intravenous oxytocin,7 and it appears to be associated
with a small but statistically signiﬁcant reduction in the risk of
postpartum haemorrhage when compared with oxytocin if
blood loss is between 500 and 1000 ml.5 Because ergotamine
can stimulate smooth muscle contraction and vasoconstric-
tion, it may raise blood pressure8 and rarely lead to coronary
artery spasm;9 therefore, syntometrine is contraindicated in
women with asthma, hypertension or cardiac disease.
Carbetocin was ﬁrst described in 198710 and is a long-act-
ing synthetic analogue of oxytocin, with agonist action. It has
a half-life of 40 minutes, and uterine contractions occur in
less than 2 minutes after IM or intravenous administration.11
The bioavailability is 80% after IM injection,11 and the opti-
mal dosage used in the third stage of labour is 100 micro-
gram.12 A single intravenous dose of carbetocin has been
shown to be as effective as a 16-hour intravenous oxytocin
infusion to increase uterine tone and reduce the intraopera-
tive blood loss in women undergoing elective caesarean sec-
tion.13 Another study comparing the uterotonic effect of 100
microgram intravenous carbetocin with 5 unit intravenous
oxytocin followed by 20 units intravenous oxytocin infusion
in preventing postpartum haemorrhage in women undergo-
ing caesarean section showed a signiﬁcantly lower incidence
of additional oxytocic intervention in carbetocin group com-
pared with that of oxytocin group.14 Prophylactic use of car-
betocin as uterotonic agent after vaginal delivery among
women at increased risk of postpartum haemorrhage has been
published in 2004. Women given IM carbetocin required sig-
niﬁcantly less additional uterotonic intervention than those
women who had intravenous oxytocin infusion.15 Carbetocin
is well tolerated and the safety proﬁle is similar to that of
oxytocin.13,14 These data suggest that IM carbetocin may be
a good alternative to IM syntometrine that is commonly used
to prevent postpartum haemorrhage. We therefore conducted
this randomised trial to compare the efﬁcacy and safety of IM
carbetocin with IM syntometrine in managing the third stage
of labour among women without any high risk factors for
postpartum haemorrhage.
Methods
This was a prospective, double-blinded, randomised study
conducted from July 2004 to March 2005 in the delivery suite
of a university hospital in Hong Kong. Women with a single-
ton pregnancy achieving vaginal delivery beyond 34-week
gestation were eligible for the study. Exclusion criteria
included the presence of contraindications for the use of
either syntometrine or carbetocin that include pre-existing
hypertension, pre-eclampsia, asthma, cardiac, renal or liver
diseases. Women with high risk factors for primary postpar-
tum haemorrhage such as grand multiparity or presence of
uterine ﬁbroids and who required prophylactic oxytocin infu-
sion after delivery were excluded.
Written informed consent was obtained from eligible
women before induction or at early stage of labour by the
staff of the research team during the morning of each working
day from 8.00 hours to 12.00 hours. Women were rando-
mised to receive either 1 ml carbetocin (containing 100
microgram carbetocin) or 1 ml syntometrine (containing
5 units of syntocinon and 0.5 mg ergometrine) given as IM
injection at the end of second stage of labour. This was per-
formed by opening a sealed, consecutively numbered, opaque
envelope that contained a computer-generated code prepared
before the recruitment.
Once an eligible woman withinformedconsentwasabout to
deliver vaginally, an independent midwife would open up the
envelope and draw up the study drug. Either IM carbetocin or
syntometrine would be given by this independent midwife
upon delivery of the anterior shoulder of the baby and she
would then leave the delivery room. The women, the midwives
and doctors attending the delivery were blinded to the type of
medication injected. Oxytocin infusion, if in progress, was
stopped. The third stage of labour was managed as usual by
clamping and cutting of umbilical cord, waiting for signs of
placental separation and delivering the placenta by controlled
cordtraction. Additional dosesofIMsyntometrine oranintra-
venous oxytocin infusion was prescribed by the attending mid-
wife or doctor if uterine atony was suspected or diagnosed.
The primary outcome variable of this study was the drop in
haemoglobin level documented by comparing the maternal
haemoglobin concentration on admission to labour ward with
that measured 48 hours after delivery. Other secondary out-
comevariablesassessedincludedthevisuallyestimatedamount
of blood loss during delivery, the incidence of primary post-
partum haemorrhage (deﬁned as blood loss more than 500 ml)
and blood transfusion. Maternal blood pressure, pulse and
temperature were checked immediately after delivery and
repeated 30 and 60 minutes later. The duration of third stage,
the incidences of prolonged third stage (duration longer than
30 minutes), the need for manual removal of placenta or addi-
tional oxytocic were recorded. We recorded the occurrence of
nausea, vomiting, ﬂushing, headache, shivering and pain over
injection site by an interview conducted 1 hour after delivery.
Our previous study showed that the mean and standard
deviation of postpartum haemoglobin concentration change
measured 48 hours after delivery among women treated with
syntometrine was 1.34 g/dl and 1.26 g/dl, respectively.16 A
trial with a power of 90% to detect a difference of 0.5 g/dl
in the haemoglobin concentration change with an alpha of
0.05 would require a sample size of 150 in each arm.
All statistical analyses were performed using Statistical
Package for Social Science for Windows version 11.0 (SPSS
Inc., IL, USA). Differences between the carbetocin and syn-
tometrine groups were compared using the chi-square test or
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continuous data. Where appropriate, relative risk (RR) and
95% conﬁdence intervals (CI) were calculated. P value of less
than 0.05 (P < 0.05) was considered as statistically signiﬁcant.
The study protocol was approved by the Clinical Research
Ethics Committee of the Faculty of Medicine of the Chinese
University of Hong Kong. All women were required to give
their written informed consent at the time of recruitment.
Results
The ﬂow chart of inclusion, exclusion and randomisation of
women is shown in Figure 1. There were a total of 3600
deliveries in our hospital during the study period, and 480
deliveries occurred in women admitted to the delivery suite
during the research recruitment hour of each morning. A total
of 329 women were ﬁnally recruited into the study. Fifteen
women in the carbetocin group and 14 women in the synto-
metrine group failed to have a paired haemoglobin test to
measure the change in haemoglobin 48 hours after delivery
eitherbecause theyhadrequestedearlyhome orrefusedfurther
bloodtaking.These 29womenwere excluded,andwe therefore
had 150 women each in the carbetocin and syntometrine arm
in the analysis. There was no signiﬁcant difference between the
two groups in their demographic characteristics (Table 1).
The mean drop of haemoglobin concentration after delivery
was 1.4 g/dl in carbetocin group and 1.5 g/dl in syntometrine
group,andthedifferencewasnotsigniﬁcant.Thehaemoglobin
concentration dropped >10% in 50 and 54.7% of women and
dropped >20% in 16 and 22% of women in the carbetocin and
syntometrine group, respectively (Table 2).
There was no signiﬁcant difference in the amount of esti-
mated blood loss and the incidence of primary postpartum
haemorrhage (‡500 ml) or severe primary postpartum hae-
morrhage (‡1000 ml) in both groups. One nulliparous woman
in the syntometrine group developed massive postpartum
haemorrhage of 2 l after vacuum extraction because of uterine
atony and retained cotyledon. All cases of primary postpartum
haemorrhage occurred either immediately or within 1 hour
postdelivery while the woman was still in the delivery room.
3600 total deliveries during the study period
from July 2004 to March 2005
220 deliveries by elective caesarean section
2900 deliveries from women admitted out of
research recruitment hour*
480 deliveries from women admitted to delivery
suite during the research recruitment hour* 
67 deliveries did not meet inclusion criteria:
multiple pregnancy, preterm <34 weeks, those
contraindicated for the drugs and those with
high risk factors for PPH
413 eligible women for study recruitment
8 refused consent
76 delivered by emergency caesarean section
329 women were randomised
165 women received
IM carbetocin
164 women received
IM syntometrine
15 women did not have
paired haemoglobin test
after 48 hours of delivery
14 women did not have
paired haemoglobin test
after 48 hours of delivery
150 women in
carbetocin group for
analysis
150 women in
syntometrine group for
analysis
Figure 1. A ﬂow chart of inclusion, exclusion and randomisation of women. PPH, postpartum haemorrhage; *8.00 to 12.00 hours of each working day.
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tion, prolonged third stage (‡30 minutes) and manual removal
of placenta were similar between the two groups (Table 3).
Adverse effects are presented in Table 4. The incidence of
nausea (RR 0.18, 95% CI 0.04–0.78) and vomiting (RR 0.1,
95% CI 0.01–0.74) were significantly lower in the carbetocin
group. The incidence of facial flushing, headache, shivering and
pain over injection site were low and similar in both groups.
Thirty-two percent of women in the carbetocin group had
tachycardia(definedasmaternalpulse‡100)within60minutes
postdeliveryandwassignificantlyhigherthanthe19%recorded
in the syntometrine group (RR 1.68, 95% CI 1.03–3.57). The
mean blood pressure values at different intervals after delivery
of each group are shown in Table 4. The incidence rate of
hypertension (deﬁned as blood pressure ‡140/90 mmHg) at
30 and 60 minutes after delivery was 5.3 and 4% in the synto-
metrine group while no woman in the carbetocin group had
raised blood pressure, and the difference was signiﬁcant.
Discussion
This study shows that using carbetocin as a routine uterotonic
drug administered as part of the active management of the
third stage in uncomplicated labour and delivery is as effective
as syntometrine but with a better adverse effect proﬁle. The
comparative efﬁcacy and its excellent tolerance are consistent
with other studies where it was given after caesarean section
or to women at high risk of postpartum haemorrhage.13–15 IM
route is the most common and convenient route to admin-
ister uterotonic agents after vaginal delivery. Therefore, we
designed this study to compare the efﬁcacy of IM carbetocin
with IM syntometrine. Our results suggest that IM carbetocin
could be an alternative to IM syntometrine for the vast major-
ity of the low-risk obstetric population.
We did not demonstrate any difference in the amount of
blood loss during delivery, the incidence of primary postpar-
tum haemorrhage and the need of additional oxytocic injec-
tion between the two groups. Despite the low incidence of
postpartum haemorrhage in both treatment groups of our
women, about 50 and 20% of the whole study group had
more than 10 and 20% drop in haemoglobin level within 48
hours, respectively. These ﬁgures were consistent with our
previous studies conducted in a similar population7,16 and
conﬁrmed that the clinical estimation of blood loss in child-
birth is inaccurate.17,18 These suggested that the conventional
deﬁnition of postpartum haemorrhage of blood loss > 500 ml
is of little clinical use, and we agreed a peripartum fall in
haemoglobin level more than 10% as the recommended diag-
nostic criteria for primary postpartum haemorrhage.19 We
therefore used the haemoglobin drop as our primary outcome
measure in assessing the efﬁcacy of the uterotonic agents in
Table 1. Demographic characteristics of the study population
Characteristics Carbetocin
(n 5 150)
Syntometrine
(n 5 150)
Age (years)* 28.3 (5.1) 28.6 (5.6)
Gestation at delivery (weeks)** 39.2 (1.6) 39.4 (1.4)
Nulliparous** 91 (60.7) 92 (61.3)
Previous postpartum haemorrhage** 0 (0) 1 (0.7)
Previous manual removal of placenta** 1 (0.7) 0 (0)
Spontaneous onset of labour** 90 (60) 101 (67.3)
Induction of labour** 60 (40) 49 (32.7)
Augmentation with syntocinon** 28 (18.7) 30 (20)
Epidural analgesia** 30 (20) 32 (21.3)
Normal vaginal delivery** 114 (76) 113 (75.3)
Vacuum extraction** 30 (20) 32 (21.3)
Forceps delivery** 6 (4) 5 (3.3)
Episiotomy** 141 (94) 136 (90.7)
Genital tract trauma** 12 (8) 18 (12)
Birth weight (g)* 3204 (443) 3225 (407)
There is no signiﬁcant difference between the two groups.
*Data are presented as mean (SD).
**Data are presented as n (%).
Table 2. Peripartum haemoglobin concentration
Carbetocin
(n 5 150)
Syntometrine
(n 5 150)
Mean
difference
RR 95% CI
Haemoglobin at onset of labour (g/dl)* 11.6 (1.1) 11.8 (1.2) 20.2 — 20.5 to 0
Haemoglobin on postpartum day 2 (g/dl)* 10.2 (1.4) 10.4 (1.5) 20.2 — 20.5 to 0.2
Mean fall in haemoglobin (g/dl)* 1.4 (1.1) 1.5 (1.3) 20.1 — 20.4 to 0.2
Mean percent drop in haemoglobin concentration* 11.6 (9.4) 12.2 (10.3) 20.6 — 22.8 to 1.7
Percent drop of haemoglobin**
.20% 24 (16) 33 (22) — 0.72 0.3–1.21
.10% 75 (50) 82 (54.7) — 0.91 0.77–1.90
*Data are presented as mean (SD).
**Data are presented as n (%).
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globin change 48 hours instead of 24 hours after delivery to
provide longer time for haemodynamic equilibrium. In our
study, the mean fall in haemoglobin, the incidence of >10%
and >20% drop in haemoglobin level, were lower in carbeto-
cin group compared with that of the syntometrine group, but
the difference was insigniﬁcant. Our data therefore suggest
that IM carbetocin is as effective as syntometrine in prevent-
ing postpartum haemorrhage.
Earlier studies where 200 microgram IM carbetocin given
immediately after birth found a higher incidence of retained
placenta,12 and other subsequent studies have delayed admin-
istration until after delivery of the placenta.15 In our study, we
administered 100 microgram carbetocin IM after the delivery
Table 3. Secondary outcomes
Carbetocin
(n 5 150)
Syntometrine
(n 5 150)
Mean
difference
RR 95% CI
Mean blood loss (ml)* 232 (122) 249 (175) 217 — 251 to 18
Primary postpartum haemorrhage** 6 (4) 3 (2) — 2.00 0.50–8.32
Blood loss  500 ml** 6 (4) 2 (1.3) — 3.00 0.61–15.53
Blood loss  1000 ml** 0 1 (0.7) — — —
Repeat oxytocic injection** 13 (8.7) 10 (6.7) — 1.30 0.56–3.13
Need of blood transfusion** 5 (3.3) 2 (1.3) — 2.50 0.49–13.36
Manual removal of placenta** 1 (0.7) 3 (2) — 0.33 0.03–3.20
Mean duration of third stage* (minutes) 11.6 (17.4) 10.4 (4.2) 1.2 — 21.7 to 4.1
Duration of third stage (minutes)**
10 128 (85.3) 126 (84) — 1.02 0.59–2.08
11–30 21 (14) 23 (15.3) — 0.91 0.47–1.71
.30 1 (0.7) 1 (0.7) — 1 0.06–16.14
*Data are presented as mean (SD).
**Data are presented as n (%).
Table 4. Adverse effects proﬁle
Carbetocin
(n 5 150)
Syntometrine
(n 5 150)
Mean
difference
RR 95% CI
Nausea* 2 (1.3) 11 (7.3) — 0.18 0.04–0.78
Vomiting* 1 (0.7) 10 (6.7) — 0.10 0.01–0.74
Facial ﬂushing* 0 3 (2) — — —
Headache* 1 (0.7) 2 (1.3) — 0.50 0.05–5.54
Shivering* 2 (1.3) 6 (4) — 0.33 0.06–1.63
Pain over injection site* 0 1 (0.7) — — —
Tachycardia (pulse  100 beats per minute)
within 60 minutes postdelivery*
32 (21.3) 19 (12.7) — 1.68 1.03–3.57
Mean systolic blood pressure immediately after delivery** 113.7 (11.6) 116.7 (12.9) 23.0 — 25.7 to 20.2
Mean diastolic blood pressure immediately after delivery** 63.4 (9.2) 67.2 (9.4) 23.8 — 26.0 to 21.7
Mean systolic blood pressure 30 minutes after delivery** 112.9 (10.3) 118.1 (11.6) 25.2 — 27.8 to 22.8
Mean diastolic blood pressure 30 minutes after delivery** 64.5 (8.4) 68.1 (10.0) 23.6 — 25.7 to 21.5
Mean systolic blood pressure 60 minutes after delivery** 113.3 (10.5) 117.1 (11.9) 23.8 — 26.4 to 21.3
Mean diastolic blood pressure 60 minutes after delivery** 64.7 (8.7) 67.9 (8.8) 23.2 — 25.2 to 21.2
Hypertension (blood pressure  140/90 mmHg)*
Immediately after delivery 2 (1.3) 4 (2.7) — 0.5 0.09–2.74
30 minutes after delivery 0 8 (5.3)*** — — —
60 minutes after delivery 0 6 (4)**** — — —
*Data are presented as n (%).
**Data are presented as mean (SD).
***P , 0.01 by Fisher‘s exact test.
****P , 0.05 by Fisher’s exact test.
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mimic active management of the third stage of labour. Only
1 of 150 women (0.7%) in the carbetocin group required
manual removal of retained placenta, and this was lower than
the 2% in women in the syntometrine group, although the
difference was statistically insigniﬁcant.
Carbetocinhasalowincidenceofadverseeffects.Nauseaand
vomiting was recorded in 7.3 and 6.7% of women in the syn-
tometrinegroupandtheincidencewassigniﬁcantlyhigherthan
the 1.3 and 0.7% in the carbetocin group. Nausea and vomiting
caused by syntometrine was also observed in our previous stud-
ies with similar incidence.7 Similar to oxytocin, carbetocin is
less likely to cause hypertension than syntometrine. High blood
pressure was recorded in 5.3 and 4% of women 30 and 60
minutesafterdeliveryinthesyntometrinegroupandnonewere
recorded in the carbetocin group. Previous studies have shown
that carbetocin could induce maternal tachycardia and facial
ﬂushing,11,12,20 and 21% of women in carbetocin group did
experience tachycardia, and the incidence was signiﬁcantly
higher than that in the syntometrine group. Although tachy-
cardia is usually transient and is not a serious problem, it may
confound monitoring of women with bleeding where haemo-
dynamic decompensation is often picked up through increases
in heart rate before changes in the blood pressure. None of our
women in the carbetocin group had facial ﬂushing and the
incidence was also low in women in the syntometrine group.
Conclusion
IM carbetocin is as effective as IM syntometrine in preventing
postpartumhaemorrhage after vaginal delivery in the low-risk
obstetric population. Carbetocin is less likely to induce hyper-
tension than syntometrine. Although it is more costly, it has
a low incidence of adverse effect. Carbetocin should be con-
sidered as a good alternative to conventional uterotonic
agents used in managing the third stage of labour. Further
studies on the use of carbetocin in women suspected or diag-
nosed to have hypertensive disorder or pre-eclampsia is
needed to see if it could become the drug of choice for this
subgroup of pregnant women.
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